Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Lung Cancer Symptoms
    • Lung Cancer Risk
    • Causes of Lung Cancer
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Lung Cancer

FDA Grants Breakthrough Therapy to Olomorasib to Treat Lung Cancer

Posted on September 8, 2025
Post Views: 1

Lung CancerEli Lilly and Company has announced that US Food and Drug Administration (FDA) has granted breakthrough therapy designation to olomorasib, in combination with anti-PD1 therapy Keytruda for first-line treatment of patients with unresectable advanced or metastatic non-small cell lung cancer (NSCLC). The Breakthrough Therapy designation aims to expedite the development and review of drugs that intend to treat a serious health issue when preliminary clinical evidence indicates that drug may improve on a clinically significant endpoint over already available therapies.

This FDA Breakthrough Therapy designation is based on encouraging results from phase ½ LOXO-RQS-20001 trial and dose optimization portion of the phase 3 SUNRAY-01 trial. This study evaluates the safety, tolerability and preliminary efficacy of olomorasib in patients with KRAS G12C-mutant advanced solid tumors. Olomorasib is currently being studied in KRAS G12C-mutated cancers in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced NSCLC, in combination with immunotherapy for treatment of resected and unresectable NSCLC.

The company stated that the updated results from an integrated analysis of these studies are to be presented at 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. Olomorasib in combination with pembrolizumab has demonstrated promising anti-tumor activity. Olomorasib is an orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity.

Dr. David Hyman, Lilly chief medical officer, in a statement in the news release, “We look forward to presenting updated data from the olomorasib development program in significantly more patients and with longer follow-up at WCLC and continuing to investigate olomorasib in combination with immunotherapy-based regimens in a variety of treatment settings across the phase 3 SUNRAY-01 and SUNRAY-02 studies.”

The information shared in this blog is for educational purposes only. You should always consult with your healthcare provider for any medical needs.

Subscribe to our newsletter or follow us on Facebook or X today to stay informed and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,586)
  • Lung Cancer: Symptoms and Treatment (5,889)
  • What is Non-Small-Cell Lung Cancer? (5,778)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • FDA Grants Breakthrough Therapy to Olomorasib to Treat Lung Cancer September 8, 2025
  • MSU Researchers Discovered Honeybees can Detect Lung Cancer September 1, 2025
  • Study Sheds Light on Rare Form of Lung Cancer August 25, 2025
  • FDA Approves Hernexeos for HER2-Mutant Advanced Lung Cancer August 18, 2025
  • Silent Symptoms of Lung Cancer – Need for Their Timely Identification August 11, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d